A recent study from the Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [2] Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [3] Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [4] Metastasis Research Center, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA shows that“IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.” This study was published in the 29 January 2015 issue of the Journal “Nature” (the no.1 journal in Science; and I.F:42) by Prof. Flores ER, Venkatanarayan A and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based therapy for p53-deficient tumors: Sirtuin2 suppresses & increases the expression of DNp63α & IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene.
Significance: Cancer suppressor p53 is mutated in more than 50% of cancers of different origin, while its pathway is altered in about 80% of tumors. This study suggests a therapeutic strategy as to how p53-deficient or mutant p53 expressing human cancers can be cured by suppressing its “oncogenic version of homologous protein p63” such as DNp63α.
It has been shown that Sirtuin2 functions as a tumor suppressor in skin. This study suggests that, Sirtuin2, by suppressing the expression of its target gene, it may decrease the expression of DNp63α; and thereby increase the expression of IAPP (Amylin). Thus, pharmacological formulations encompassing “Sirtuin2 activators” can be used to inhibit the progression of p53-deficient human tumors, including melanoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Web: http://genomediscovery.org
Citation: Boominathan, Small molecule-based therapy for p53-deficient tumors: Sirtuin2 suppresses & increases the expression of DNp63α & IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene, 6/May/2015, 11.41 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Undisclosed information: How Sirtuin2 suppresses the expression of DNp63α and increases the expression of IAPP
* Research cooperation